Antiviral prodrugs and nanoformulations thereof

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein R is a saturated linear aliphatic chain of a length of 17 carbons.

2. A nanoparticle, comprising a compound of claim 1 and a polymer or surfactant.

3. The nanoparticle of claim 2 , wherein said compound is

or a pharmaceutically acceptable salt thereof, and the polymer or surfactant is P407.

4. A pharmaceutical composition, comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.

5. A method of treating an HIV infection in a subject in need thereof, wherein said method comprises administering to said subject a therapeutically effective amount a pharmaceutical composition of claim 4 .

6. The method of claim 5 , wherein the pharmaceutical composition is administered via injection.

7. The method of claim 5 , wherein the pharmaceutical composition is administered one time in a 3, 6, 9, 12, 18, or 24 month period.